Decision Support Tool for Patients With Advanced Breast Cancer
Part of paid clinical trials in Brooklyn, New York.
- Sponsor
- Weill Medical College of Cornell University
- Study ID
- NCT07635147
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Advanced Breast Cancer
- Breast Cancer Metastatic
- Stage 4 Breast Cancer
- Stage IV (Metastatic) Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Decision Support Tool — BEHAVIORALThe COAST decision support tool will be available in two formats: a booklet and a website. It will provide information about advanced breast cancer and the available treatment options. Participants will be guided through questions designed to clarify their goals and preferences, identify support needs, and concerns they may have.
Study Details
The goal of this pilot study is to understand and improve the shared decision-making process between people with advanced breast cancer and their providers regarding their care and treatment. As part of this study, the researchers will evaluate a decision support tool called COAST that was designed to support patients and providers in having meaningful conversations. The main questions it aims to answer are: 1. Can the COAST tool improve the quality of communication between patients and their oncology providers? 2. Is the COAST tool acceptable, appropriate, and easy to use at NYP-Weill Cornell Medicine, NYP-Brooklyn Methodist Hospital and NYP-Queens? Participants will be asked to fill out two surveys: one before they use the COAST tool and another about 2 - 4 weeks later. Some patients will also be invited for an interview.
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- Jun 2026
- Primary completion
- Sep 30, 2027
- Completion
- Feb 29, 2028
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: COAST intervention
Primary Outcome Measure
Patient-reported acceptability of the COAST decision support tool [ Time Frame: 2-4 weeks after exposure to COAST ]
Central Contacts
- Zori K Hamilton, MA646-962-3694
- Darima Dorzhieva646-962-8666
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NewYork-Presbyterian Brooklyn Methodist Hospital | Brooklyn | New York | 11215 | Evelyn Taiwo, MD (PRINCIPAL_INVESTIGATOR) |
| NewYork-Presbyterian David H. Koch Center | New York | New York | 10065 | Shoshana Rosenberg, ScD, MPH (PRINCIPAL_INVESTIGATOR) |
| NewYork-Presbyterian Medical Group Queens | New York | New York | 11355 | Pooja Murthy, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Brooklyn, NY
Related Studies
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsPHASE1 · Recruiting · General Oncology, Inc. · Boston, Massachusetts
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPHASE1 · Recruiting · Relay Therapeutics, Inc. · Tucson, Arizona
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerPHASE1/PHASE2 · Recruiting · Incyclix Bio · Orlando, Florida
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerPHASE3 · Recruiting · Olema Pharmaceuticals, Inc. · Tucson, Arizona